Home › Funds › ARCH Venture Management, LLC › LYEL

ARCH Venture Management, LLC position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

ARCH Venture Management, LLC reported holding 3,247,162 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$45.5M, representing 4.14% of its reported portfolio and ranking #8 among its reported holdings. ARCH Venture Management, LLC has disclosed LYEL holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)3.25M sh
Reported value held$45.53M
Portfolio Weight4.14%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARCH Venture Management, LLC's LYEL position evolved

ARCH Venture Management, LLC first disclosed a stake in LYEL in Q2 2025 at 1,820,634 shares (US$16.1M). The position peaked in Q4 2025 at 2,759,072 shares, worth US$84.9M. Across 5 filings, ARCH Venture Management, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 3,247,162 shares valued at US$45.5M. Notable position changes include a 52% increase in Q3 2025 (shares rose 90% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 1.82M $16.11M New
Q3 2025 2.76M $44.81M Add
Q4 2025 2.76M $84.92M Hold
Q1 2026 3.25M $65.14M Add
Q2 2026 3.25M $45.53M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M), Decheng Capital LLC (US$9.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has ARCH Venture Management, LLC held LYEL?

ARCH Venture Management, LLC has disclosed LYEL holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is ARCH Venture Management, LLC's current position in LYEL?

As of Q2 2026, ARCH Venture Management, LLC holds 3.25M shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $45.53M, representing 4.14% of its reported portfolio and ranking #8.

Has ARCH Venture Management, LLC been buying or selling LYEL?

In the latest 13F filing (Q2 2026), ARCH Venture Management, LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 2.76M shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include GSK plc, Orland Properties Ltd, Decheng Capital LLC, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.